NCT05867030 2023-10-17
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Withdrawn
Clinical Trials
6 trialsNCT04635683 2022-09-30
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT03506802 2020-07-24
NYSCT MM
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT03373305 2019-04-30
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
City of Hope Medical Center
Phase 1 Withdrawn
NCT03591744 2018-12-19
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
City of Hope Medical Center
Phase 1 Withdrawn
NCT03283046 2017-09-20
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Withdrawn